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Direct-to-Consumer Marketing of Predictive 
Medical Genetic Tests: Assessment of Current 
Practices and Policy Recommendations 
Yuping Liu and Yvette E. Pearson 
This research reviews the current state of affairs in the fast-growing area of direct-to-consumer 
marketing of genetic tests. The authors identify the unique nature of genetic tests and the ensuing 
consumer vulnerability. They also present a comprehensive examination of the current legal 
environment and an empirical analysis of genetic testing companies' online marketing practices. On 
the basis of the analysis and review, they make a set of policy recommendations that consists of 
consumer education, physician intervention and education, and direct regulation of marketing 
activities, especially as they relate to the online medium. 
Keywords: genetic testing, direct-to-consumer marketing, public policy, health care, Internet marketing 
With the completion of the Human Genome Project in April 2003, medical genetic tests have become 
more popular and have received a lot of media 
attention. Currently, genetic tests for more than 1200 dis-
eases are available to consumers (Javitt 2007), and this 
number is likely to grow as additional disease-related genes 
are identified. Rapid developments in genetics have led to 
the quick growth of companies that market predictive 
genetic tests and have spawned a profitable marketplace 
expected to be worth $12.5 billion by 2009 (Alsever et al. 
2006). According to its annual reports, Myriad Genetics 
(2007), a leading marketer of medical genetic tests, experi-
enced a growth of 44% as its molecular diagnostic test reve-
nues increased from $100.6 million in 2006 to $145.3 mil-
lion in 2007. 
Although genetic testing has traditionally been available 
to patients through their physicians, some companies have 
begun direct-to-consumer (DTC) marketing of genetic tests 
through the Internet or retail pharmacies. Some of these 
companies market at-home genetic tests that can be con-
ducted by simply swabbing inside the consumer's cheek. 
This direct access to genetic tests offers consumers poten-
tial benefits, such as lower cost, more privacy with testing, 
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and increased awareness of genetic diseases. According to a 
Harris Interactive poll (Taylor 2002), more than two-thirds 
of adults surveyed were willing to undergo reasonably 
priced genetic tests, and nearly half claimed that they would 
ask for a genetic test even if nothing could be done to pre-
vent or treat the target disease. 
The growing DTC marketing of genetic tests combined 
with heightened public interest suggests a need for more 
public policy attention to this area. Currently, genetic test-
ing services are not regulated consistently across the United 
States, and existing federal regulations are minimal and 
often confusing or ineffective insofar as they fail to better 
inform or protect prospective consumers of genetic testing 
services. Although some states allow only physicians to 
order genetic tests, such restrictions are inconsistent across 
states and are unlikely to affect online sales of genetic test-
ing services because the authority of individual states does 
not clearly extend into the online environment (Genetics 
and Public Policy Center [GPPC] 2007c). There are also 
questions about the clinical value of many genetic tests 
(Gollust, Wilfond, and Hull 2003). Repeated calls to the 
Centers for Medicare and Medicaid Services (CMS) and the 
Food and Drug Administration (FDA) to improve regula-
tion and oversight of genetic testing service providers have 
been largely ignored. A recently released report by the 
GPPC (see Javitt and Hudson 2006b) further confirms the 
failure in oversight of genetic testing laboratories and the 
need for vast improvements in the current regulatory 
climate. 
As we discuss subsequently, the combination of con-
sumer ignorance, scant government regulation, aggressive 
marketing practices, and the often overzealous media atten-
tion to genetic testing is a recipe for harm to individual con-
sumers and public health. Although the probable negative 
outcomes of DTC sales of genetic testing services are not 
yet fully understood, problems with DTC marketing of 
pharmaceutical drugs suggest the need for careful scrutiny 
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of DTC marketing of genetic tests. Some researchers have 
documented consumers' misconceptions about government 
oversight and the validity of information presented in 
advertisements (Wilkes, Bell, and Kravitz 2000). Others 
have noted consumers' inability to comprehend the content 
of drug advertisements (Weissman et al. 2004; Wilkes, 
Bell, and Kravitz 2000) or to determine accurately whether 
a particular drug is appropriate (Lexchin and Mintzes 
2002).1 Given the greater complexity of genetic informa-
tion, consumers' failure to understand and properly use 
DTC information can result in undesirable outcomes, such 
as the use of an unnecessary or a low-quality test, needless 
anxiety about test results, a false sense of security or doom, 
harmful health and lifestyle choices, and inappropriate use 
of health care services (Hudson et al. 2007). Thus, it is 
important for marketing researchers, bioethicists, and those 
working in the field of business ethics to reflect carefully on 
DTC marketing practices and the context in which they 
occur so that harm to consumers and public health can be 
avoided. 
To this end, this research assesses the current state of 
DTC marketing of genetic tests and services. As far as we 
know, this is the first comprehensive examination of the 
topic in the marketing field. In our analysis, we evaluate 
both business practices and government regulation of such 
practices. This includes an empirical examination of DTC 
marketing of genetic tests on the Internet, currently a major 
medium for marketing activities in this area. Through such 
analyses, we identify the potential benefits and problems 
with DTC sales of genetic testing services. Finally, we 
formulate a set of ethically sound public policy recom-
mendations in this area. We begin with a brief description 
of genetic tests. 
A Primer on Genetic Testing 
A gene is a sequence of deoxyribonucleic acid (DNA) that 
codes for a specific function. Most genes provide instruc-
tions for the creation of proteins, which are sometimes 
called the "building blocks of life." A "permanent structural 
alteration in DNA" can occur, which is called a mutation 
(see http://www.genome.gov). Although some mutations 
have no effect, others contribute to impaired functioning of 
the organism. For example, a deletion of part of the DNA 
sequence in BRCAl, a tumor-suppressor gene, is a risk fac-
tor for increased susceptibility to a certain type of breast or 
ovarian cancer. Genetic tests aim to identify the presence of 
such mutations. In this research, we focus on one class of 
genetic tests-namely, predictive genetic tests, which 
include both tests that determine whether an individual is a 
carrier who can pass a gene to the offspring and tests that 
assess whether the individual him- or herself has an 
increased susceptibility to a disease. 
Ideally, a genetic test should be analytically valid. Two 
components of analytical validity are sensitivity, which 
refers to how often a test is positive when the mutation is 
present, and specificity, which refers to the frequency of a 
!Note that diverse opinions exist on the effects of OTC marketing of 
prescription drugs and that not everyone believes it is harmful. For a 
review of arguments on both sides, see Auton (2004) and Lexchin and 
Mintzes (2002). 
negative result when the mutation is absent. Because ana-
lytical validity alone does not guarantee that the test will be 
valuable for patient management, it is also important to 
consider the value of a test in the clinical setting (i.e., clini-
cal validity and utility). A gap between analytical and clini-
cal validity occurs if the detection of a mutation does not 
correspond to symptoms observed in patients. 
A common misunderstanding about predictive genetic 
testing is that it provides definite knowledge of the future. 
Although there are some rare diseases (e.g., Huntington's 
disease) for which having the gene means that the person 
will definitely get the disease, most diseases, including 
more common afflictions, such as cancers and diabetes, do 
not follow this straightforward pattern. Because many dis-
eases are caused by gene-gene or gene-environment inter-
action, a genetic mutation alone may be neither necessary 
nor sufficient for the manifestation of a disease. As a result, 
knowledge that a person carries a particular mutation is 
often of limited value. Contrary to the prevalent false 
assumption of genetic determinism-the belief that future 
health status is determined entirely by genetic makeup-
having a mutation does not guarantee that a person will get 
a disease associated with a particular mutation. 
Both analytical and clinical validity can diverge from 
clinical utility if there are no preventive or curative mea-
sures for patients who carry what is believed to be a harm-
ful mutation. Although the negative effects of some dis-
eases (e.g., Phenylketonuria) are currently preventable with 
knowledge that a person carries a "bad" gene, the medical 
profession lacks not only preventive or curative measures 
but also treatments for many genetic diseases. However, the 
widespread publicity of the Human Genome Project has 
caused excessive optimism regarding the probability and 
proximity of procuring clinical benefits from emerging 
genetic technologies (Burke 2004; Conrad 2002). As Burke 
(2004, p. 9) points out, "the predictive power of genetic 
information is routinely overestimated, and testing possi-
bilities that are no more than research ideas are presented 
as imminently available." Although the results of some 
genetic tests may be valuable to the patient, there is good 
reason to be cautious when making claims regarding the 
ability of genetic tests to contribute to more effective clini-
cal care or improved patient health. 
OTC Marketing of Genetic Tests: 
Promises and Perils 
Emerging Trends in Genetic Testing 
Genetic testing is not new, but the application of genetic 
tests has been changing in recent years. First, the way 
genetic testing is done is changing. In the past, physicians 
would order genetic tests as part of a broader panel of diag-
nostic tests and procedures or as part of a screening pro-
gram. Although genetic testing is still done mainly through 
physicians, consumers can now undergo genetic testing at 
home. A typical at-home genetic test entails consumers col-
lecting their own sample, sending it to a lab for analysis, 
and then receiving the results in the mail or through the 
Internet. An increasing number of genetic tests are offered 
through such means, and companies selling these tests have 
stepped up their DTC marketing efforts. 
Second, the rationale for undergoing genetic tests is also 
shifting. Until recently, genetic testing has been diagnostic 
and restricted mainly to prenatal and newborn testing (Tay-
lor, Edwards, and Ku 2006). Increasingly, however, genetic 
testing is motivated by a desire to determine what might be 
rather than attempting to confirm a tentative diagnosis of a 
genetic disease. An asymptomatic adult may request a 
genetic test because his or her family history indicates 
affliction with a disease, or the person may simply be curi-
ous about whether he or she carries any genes that have 
been linked with an increased risk of a disease. 
Finally, genetic testing is also rapidly broadening beyond 
rare, single-gene disorders that have a simple inheritance 
pattern (e.g., Huntington's disease). An increasing number 
of predictive genetic tests now target common diseases 
(e.g., cancers, cardiovascular diseases) that are more geneti-
cally complex. These tests ostensibly allow patients to learn 
whether they carry genes associated with increased suscep-
tibility to common diseases. This scenario poses new prob-
lems in terms of interpretation and clinical application of 
results. 
Potential Benefits of OTC Marketing of and 
Access to Genetic Tests 
Although there are legitimate concerns about the validity 
and value of many genetic tests, DTC marketing of and 
access to genetic tests may benefit some consumers. First, 
DTC marketing can raise awareness of genetic diseases and 
the availability of genetic tests, and this may encourage 
patients to visit a health care professional to learn more 
about a genetic test or hereditary disease. In her discussion 
of DTC marketing of prescription drugs, Kelly (2004, pp. 
247--48, n. 7) cites a study that showed that nearly two-
thirds of "physicians serving a predominantly [African 
American] population reported that patients have come in 
solely because of a DTC ad." Second, Racine, Van der 
Loos, and Illes (2007) note that people who have or suspect 
they have a stigmatized illness (e.g., herpes, depression, 
incontinence) are more reluctant to seek help through tradi-
tional means because, for example, even visiting a psychia-
trist suggests that a person has a mental illness. In the realm 
of genetic testing, we can imagine that a person who sus-
pects that he or she has a hereditary form of a stigmatized 
illness might prefer to avoid going to a physician or genetic 
counselor to conceal his or her quest for personal genetic 
information. Because DTC access to genetic tests bypasses 
the traditional health care hierarchy, it may offer consumers 
greater privacy and thus reduce such psychological barriers. 
Relatedly, with fewer people sharing the information, DTC 
genetic tests may also keep genetic information out of the 
hands of those who might use it to the detriment of the indi-
vidual tested. 
Consumer Vulnerability and Its Consequences 
The realization of potential benefits provided by DTC mar-
keting of and access to genetic tests is context dependent. A 
genetic test is a unique product in that it involves complex 
information and requires a high level of knowledge for the 
product to be purchased and "consumed" properly. Existing 
research has shown that even physicians are often ill-
equipped to provide genetic services (e.g., National Insti-
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tutes of Health Task Force on Genetic Testing 1997; Tay-
lor, Edwards, and Ku 2006). Average consumers are in a 
worse epistemic position, and most of them are unable to 
protect themselves adequately or to make genuinely 
informed decisions regarding genetic tests. Because con-
sumers are encouraged to bypass rather than consult with 
genetic counselors or other relevant professionals, DTC 
marketing of genetic tests remains ethically questionable. 
For many consumers and physicians (Goddard et al. 
2007), the primary sources of information about genetics 
are the popular media and genetic test vendors, both of 
which can be misleading. The popular press is often driven 
by the enthusiasm and hype about discoveries of "disease 
genes." As a result, the public often hears a lot about excit-
ing discoveries and little, if anything, about disconfirming 
evidence or failures to replicate study results connecting 
genes to traits or maladies (Conrad 2002). Because the 
"news media are the major avenue by which information 
about genetics enters the culture," failure to properly report 
disconfirmations can lead to obsolete or false information 
becoming "fossilized in the culture" (Conrad 2002, p. 75). 
Skepticism is also warranted about the objectivity and 
scientific verifiability of information provided by marketers 
of genetic tests, given their dominantly for-profit motive. 
The limitations of marketer-supplied information have been 
well documented in the literature on DTC advertising of 
prescription drugs (Macias and Lewis 2005; Main, Argo, 
and Ruhmann 2004; Wolfe 2002). Given the weaker regu-
latory oversight of genetic testing, information supplied by 
marketers of genetic tests is likely to be even more prob-
lematic. Consistent with this view, research has shown that 
physicians' use of pharmaceutical companies as a frequent 
source of information is a negative indicator of their knowl-
edge of genetics (Hofman et al. 1993). Although the current 
situation may have changed from the much earlier study, 
our own analysis of commercial genetic testing Web sites, 
which we report on in greater detail subsequently, confirms 
the bias in the information provided by online genetic test 
marketers. Such findings raise serious doubt that consumers 
will be properly educated through existing marketing 
materials. 
Although there are good information sources on genetics, 
consumers may be unable to distinguish between accurate 
and inaccurate sources or identify bias. To make matters 
worse, although physicians often realize their own knowl-
edge deficits (Hofman et al. 1993), consumers may be 
unaware of their own ignorance of genetics and, therefore, 
unlikely to seek information. Prior research has found that 
such overconfidence is prevalent among consumers and that 
it leads to suboptimal search and purchase decisions (Alba 
and Hutchinson 2000). 
Consumers' vulnerability in the decision-making process 
regarding genetic tests can endanger their long-term health 
and welfare (Cella et al. 2002; Lee and Brennan 2002). 
Those who are neither aware of nor warned about the risk 
of false positives and false negatives are likely to overesti-
mate the significance of test results. This can induce 
unfounded anxiety and fear or a false sense of security in 
test takers. People genetically related to someone who 
undergoes genetic testing may also be affected nonvoluntar-
ily by test results. Although there is some debate about 
whether and to what extent genetic test results affect patient 
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behavior, a recently released statement from the American 
Society of Human Genetics warns of the possibility of con-
sumers making irrevocable decisions based on these results 
(Hudson et al. 2007). In the news, there have been multiple 
accounts of people making life-altering decisions based on 
genetic test results (usually combined with knowledge of 
their family history relative to the disease in question). For 
example, some women have reportedly had their breasts 
and ovaries removed when a genetic test revealed that they 
carried a mutation of the BRCAl (or BRCA2) gene (Herel 
2002). Burke and colleagues (2002) also note that a fatalis-
tic attitude may result from knowledge of personal genetic 
risk. Along similar lines, De Melo-Martin (2006b) argues 
that relying on genetic tests as a means to ameliorate human 
suffering might prevent people from making necessary 
changes to the social contexts and institutions that con-
tribute to the perpetuation of disease and disability. From a 
social welfare perspective, undergoing unnecessary testing 
and subsequently seeking remedial measures can overbur-
den the health care system and divert precious resources 
from practices and procedures that have a much higher clin-
ical value. 
Current Regulation of Genetic Tests 
The recently passed FDA Amendments Act of 2007, which 
requires the Secretary's Advisory Committee on Genetics, 
Health, and Society to complete an assessment of the qual-
ity and safety of genetic tests, is just one manifestation of 
justified concern about the current lack of regulation of 
genetic testing services. However, the GPPC notes that the 
lack of regulation and oversight is not due to a shortage of 
recommendations from task forces or advisory committees 
(GPPC 2007a; Javitt and Hudson 2006b). In particular, over 
a decade ago, the Institute of Medicine conducted an 
inquiry that addressed precisely these issues and made rec-
ommendations. Other large-scale studies were conducted by 
the 1995 National Institutes of Health Task Force on 
Genetic Testing and the 2000 Secretary's Advisory Council 
on Genetic Testing. Researchers have explained repeatedly 
that policy makers and public agencies should implement 
the recommendations that have been put forth (e.g., Javitt 
and Hudson 2006a, b). Thus far, however, policy makers, 
including legislators, are either unsure of how to proceed or 
unwilling to create and enforce much needed regulations. 
Currently, certain parts of the genetic testing process are 
governed by a few federal regulations that were not formu-
lated specifically for genetic tests. One such regulation is 
the Clinical Laboratories Improvement Amendments 
(CLIA) of 1988, which is administered by the CMS. The 
goal of the CLIA is to "ensure quality laboratory testing." 
However, the CUA does not "address the inherent safety 
and effectiveness" of genetic tests (Andrews et al. 1994, 
p. 136), and it does not regulate laboratories' claims about 
such tests (Hudson et al. 2007). Until August 2006, the 
CMS appeared to be moving toward developing a specialty 
area for genetic testing, but it suddenly decided that it was 
not vital to do so (Javitt and Hudson 2006b). The absence 
of a specialty area in genetics threatens both the analytic 
and the clinical validity of genetic tests. Although the CLIA 
addresses only analytic validity, that analytic validity is a 
necessary but not sufficient condition for clinical validity or 
utility means that knowledge of a test's analytic validity 
would clarify which tests are definitely not going to be 
clinically valuable. 
In addition to the CLIA, the FDA provides oversight over 
some genetic testing services, mainly in the area of premar-
ket approval, but significant ambiguity remains about the 
FDA's regulatory authority over genetic testing services. 
Only genetic tests marketed as kits are under direct FDA 
regulation as in vitro diagnostic devices, but because most 
genetic tests are not marketed as kits, they can sidestep 
FDA approval. Javitt (2007) notes that the FDA has 
approved only eight genetic test kits, which indicates a pref-
erence on the part of test manufacturers to evade regulation. 
In addition to regulating in vitro diagnostic devices, the 
FDA also regulates "analyte-specific reagents," which it 
classified as medical devices in 1997. Analyte-specific 
reagents are the active ingredients in laboratory-developed 
tests, which, unlike test kits, do not include instructions and 
information regarding the purpose and proper use of a test; 
instead, the labs themselves determine the composition and 
application of tests (Javitt and Hudson 2006a). The FDA's 
regulation of analyte-specific reagents restricts their sale to 
labs, but it does not dictate their use in laboratory-
developed tests. 
Regulatory deficits become even more obvious with 
DTC marketing of genetic tests. Neither the CMS nor the 
FDA regulates the content of communications from genetic 
testing companies to the public. Advertisements for genetic 
tests are subject to the general principle of truthful advertis-
ing under Federal Trade Commission (FTC) regulations, 
which requires claims in advertisements to be true and sub-
stantiated (FTC 1984a, b). However, given the complex 
nature of genetic science and consumers' lack of knowledge 
in this area, FTC regulations are likely to be inadequate to 
oversee marketing activities in the genetic testing industry. 
This contrasts with the FDA's regulation of prescription 
drug advertising (21 CPR § 202.1), which treats prescrip-
tion drugs as unique products and requires their advertise-
ments to provide true and balanced information, including 
mandatory disclosure of the drugs' harmful effects along-
side information about benefits. 
At the state level, regulation is mixed. A GPPC (2007c) 
report indicated that there are no restrictions on DTC labo-
ratory testing in 26 states and the District of Columbia. 
Only 11 states explicitly prohibit DTC access to genetic 
tests. In most states in which consumers are allowed direct 
access to genetic tests, the law says nothing. The current 
legislative silence leads to the assumption that DTC access 
to genetic tests is permissible and even desirable, though 
there is currently insufficient evidence to support such an 
assumption. 
Online OTC Marketing of Genetic Tests: 
An Empirical Assessment 
Overview 
To further assess current DTC marketing practices, we 
content-analyzed genetic testing companies' Web sites. Our 
focus on the Internet was based on consumers' increasing 
use of this medium to look for health information (Sewak et 
al. 2005; Waack, Ernst, and Graber 2004). Recent statistics 
show that 84% of U.S. Internet users have searched for 
health information online (Harris Interactive Inc. 2007), and 
more than half of the searchers reported that their most 
recent online search influenced how they cared for them-
selves or others (Fox 2006). Although large-scale advertis-
ing campaigns of genetic tests through the traditional media 
(e.g., the fall 2007 campaign by Myriad Genetics; see 
GPPC 2007b) are still rare, most genetic test marketers 
have developed a Web presence. Corporate Web sites are 
currently the main source of DTC marketing information 
and thus form the target of our empirical analysis. Similar 
to prior examinations of DTC advertising of prescription 
drugs (Macias and Lewis 2005; Waack, Ernst, and Graber 
2004), our purpose is to determine the extent to which 
information provided by DTC marketing Web sites is 
biased or incomplete and whether such information is 
merely a persuasive ploy or a useful resource that helps 
consumers make more informed decisions. By identifying 
the problems in current practices, we hope to provide help-
ful input for public policy that can eventually address these 
problems. 
Methodology 
Sample Identification 
To identify the Web sites that market genetic tests, a trained 
research assistant conducted searches using all major Inter-
net search engines first in July 2006 and again in December 
2007. Variations of keywords, such as "genetic tests" and 
"genetic testing services," were used. Online directories 
published by Yahoo and Google were also perused to iden-
tify relevant Web sites that might not have turned up during 
the search process. Of all the Web sites found, we then 
selected those that market predictive genetic testing ser-
vices. We excluded information-only Web sites and Web 
sites of companies based outside the United States, consis-
tent with our focus on regulatory issues in the United 
States. Because these classifications were fairly straightfor-
ward, we did not encounter any disagreement as to which 
ones should be included. The final list consisted of 63 Web 
sites, 46 of which had significant consumer-targeted con-
tent (see Table 1). Over five years, the number of DTC 
genetic testing sites has increased significantly, almost 
tripling the number of sites found in previous studies (Gol-
lust, Wilfond, and Hull 2003; Williams-Jones 2003). This 
shows the rapid growth of online DTC marketing by the 
genetic testing industry. Some Web sites found in previous 
searches no longer existed or had changed their corporate 
identity by the time of our search, suggesting the volatile 
nature of the marketplace. 
The other 17 Web sites in our final list targeted mainly 
health care professionals (see Table 2).2 We retained these 
Web sites and analyzed them along with the DTC site 
group. The rationale for such comparative analysis was 
2We made this distinction by considering the following: (1) clear state-
ment of Web site targeting only physicians; (2) consistent referencing of 
the reader as a health care professional (e.g., "your patients"); and (3) no 
separate page, document, or section specifically for nonprofessionals. The 
intercoder agreement was 95.0%. Disagreements between the two coders 
were resolved through discussion. 
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that, given the assumption, albeit problematic, that health 
care professionals are likely to have a higher level of 
"genetic literacy" than laypersons, it would be expected that 
they are better able to process and evaluate information 
(Alba and Hutchinson 1987), which may in tum motivate 
marketers to provide higher-quality information. However, 
our results cast doubt on some of these assumptions. In 
addition to professional versus DTC Web sites, we com-
pared the professional versus consumer sections within the 
24 DTC Web sites that had significant materials for both 
consumers and professionals.3 Because these sections 
reside within the same Web sites, such an analysis can offer 
an even more telling picture of the different ways marketers 
may treat the two segments. 
Content Coding and Data Analysis 
Following recommended content analysis procedures 
(Neuendorf 2002), our analysis was guided by a codebook, 
which contained variables related to the availability and 
quality of information and to the use of emotional appeals. 
To develop information quality criteria, we examined prior 
research on genetic testing (Gollust, Wilfond, and Hull 
2003; McCabe and McCabe 2004; Shepperd et al. 2006) 
and, more generally, on what is considered quality health 
care information (Chamock et al. 1999; Entwhistle et al. 
1996). We also drew from the field of DTC marketing of 
prescription drugs (e.g., Main, Argo, and Ruhmann 2004; 
Waack, Ernst, and Graber 2004; Woloshin et al. 2001). On 
the basis of these sources, we examined the presence/ 
absence of the following in each Web site: (1) basic infor-
mation on genetics, (2) probabilistic nature of genetics, (3) 
balanced information (i.e., both pros and cons of genetic 
testing), (4) alternatives to genetic testing, (5) privacy pol-
icy, and (6) scientific information for professionals. For the 
use of emotional appeals, we studied six positive emotional 
appeals (happiness/joy, warmth, pride, empowerment, 
assurance/peace of mind, and relief) and four negative emo-
tional appeals (fear, guilt/shame, regret, and sadness). 
These emotional appeals were drawn from existing typolo-
gies of emotions (Bagozzi, Gopinath, and Nyer 1999; Rose-
man 1991) and from studies of emotional appeals in DTC 
advertising (e.g., Main, Argo, and Ruhmann 2004; Wolfe 
2002; Woloshin et al. 2001). 
Two judges independently coded each Web site using the 
codebook. The overall intercoder agreement was 93.3%, 
the intercoder agreement for each codebook item appears 
in Table 3. Disagreements between the two coders were 
resolved through discussion. The coded data were then ana-
lyzed with SPSS. For the prevalence of a feature, we used 
frequency analysis. To compare between Web sites and 
between sections within the same DTC Web sites, we used 
chi-square analysis. For the use of emotional appeals, we 
also used t-tests to compare the total numbers of emotional 
3This comparison applies only to the 24 DTC Web sites that had both a 
consumer section and a professional section. One of the DTC Web sites, 
CyGene Direct, requires that people log in to access professional informa-
tion and is excluded from this analysis. We also note that certain features 
(e.g., privacy policy) are sometimes available as general sections of a Web 
site. In such cases, they are considered to belong to both the consumer sec-
tion and the professional section. 
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Table 1. DTC Genetic Testing Web Sites 
Doctor 
Patient Direct Intervention 
Company Name and Web Site Address Tests Offered Order Required 
23andMe (http://www.23andme.com) Comprehensive genetic profile Yes No 
Alzheimer's Mirror (http://alzmirror.com) Alzheimer's disease Yes No 
Andrology Laboratory Services Pregnancy loss No Yes 
(http://www.androlab.com) 
Baylor Health Care System Newborn screening for metabolic diseases Yes Yes 
(http://www.baylorhealth.com/medical 
specialties/metabolic/newbomscreening.htm) 
Center for Medical Genetics Cystic fibrosis, pregnancy loss, prenatal, Tay- Yes No 
(http://www.geneticstesting.com) Sachs, Bloom syndrome, and others 
Cincinnati Children's Hospital Hearing loss, metabolism, mental retardation, No Yes 
(http://www.cincinnatichildrens.org/svc/ lysosomal storage disease, and others 
topics/genetics.htm) 
Consumer Genetics Risk of heart attack and infertility due to caffeine Yes No 
(http://www.consumergenetics.com/) and wine intake 
Cygene Direct Osteoporosis, thrombosis, and others Yes No 
(http://www.cygenedirect.com/default.html) 
DNA Direct Breast and ovarian cancer, cystic fibrosis, Yes No 
(http://genesanddrugs.dnadirect.com) diabetes, and others 
DNA Traits (http://www.dnatraits.com) Fragile X, clotting disorders, sickle-cell anemia, Yes No 
and others 
Emory University Genetics Clinic Down syndrome, metabolic diseases, No Yes 
(http://www.genetics.emory.edu/clinics.php) neurofibromatosis, and others 
GenAssist (http://www.genassist.com/) Preconception and prenatal No Yes 
GeneCare Medical Genetics Center Cystic fibrosis, Tay-Sachs, hereditary No Yes 
(http://www.genecare.com/) hemochromatosis, and others 
Genelex (http://www.healthanddna.com/) Nutrigenomics and pharmacogenetics Yes No 
GeneLink (http://www.genelink.info) Oxidative stress, cardiovascular health, bone Yes No 
health, metabolism problems, aging, skin health, 
and nutrigenomics 
Genetics & IVF Institute Cystic fibrosis, Tay-Sachs, familial No Yes 
(http://www.givf.com) dysautonomia, and others 
Genova Diagnostics Cardiovascular health, osteoporosis, immune No Yes 
(http://www.genovadiagnostics.com) system health, and others 
Genzyme Genetics Cystic fibrosis, fragile X, Down syndrome, and No Yes 
(http://www.genzymegenetics.com/ others 
default.asp) 
Graceful Earth Alzheimer's disease Yes No 
(http://www.gracefulearth.com/) 
Great Lakes Genetics Cystic fibrosis, fragile X, sickle-cell anemia, and No Yes 
(http://www.genetest.com/) others 
Table 1. Continued 
Company Name and Web Site Address 
HealthCheckUSA 
(http://www.healthcheckusa.com/) 
Health Tests Direct (http://www.health-tests-
direct.com) 
HIVMirror (http://www.hivmirror.com/) 
Holistic Heal (http://www.holisticheal.com) 
InterGenetics Incorporated 
(http://www.intergenetics.com/) 
Interleukin Genetics (http://www.ilgenetics.com/) 
John Stoddard Cancer Center 
(http://johnstoddardcancer.org/body .cfm? 
id=l 1) 
Kimball Genetics 
(http://www.kimballgenetics.com/) 
LabCorp 
(http://www.labcorp.com/genetics/index.html) 
MarketAmerica 
(https://www .marketamerica.com/corporate/ 
index.cfm ?action=services. wpGeneSNPinfo) 
MyGenome (http://www.mygenome.com/) 
Myriad Genetic Laboratories 
(http://www.myriadtests.com/) 
NYU Human Genetics Program 
(http://www.med.nyu.edu/pediatrics/genetics/) 
Pediatrix (http://www.pediatrix.com/) 
PGx Health (http://www.pgxhealth.com/ 
genetictests/familion/) 
Quest Diagnostics 
(http://www.questdiagnostics.com/) 
Quixtar (http://www.quixtar.com/products/ 
product.aspx?itemno= 104009) 
Salugen (http://www.salugen.com) 
Sciona (http://www.mycellf.com) 
Signature Genomic Laboratories 
(http://www.signaturegenomics.com) 
Suracell (http://www.suracell.com) 
Tests Offered 
Celiac disease, thrombosis, and hereditary 
hemochromatosis 
Cystic fibrosis 
HIV/AIDS progression 
Nutrigenomics 
Breast cancer, cystic fibrosis, and others 
Nutrigenomics and gum disease 
Breast cancer, ovarian cancer, colorectal 
cancer, and related cancers 
Broad beta disease, celiac disease, cystic 
fibrosis, and others 
Prenatal 
Nutrigenomics 
Alzheimer's disease, thrombosis, osteoporosis, 
and others 
Breast cancer, ovarian cancer, colorectal 
cancer, endometrial cancer, and melanoma 
Cystic fibrosis, Tay-Sachs, Canavan disease, 
and others 
Newborn screening 
Heart disease 
Breast cancer 
Heart disease 
N utrigenomics 
Nutrigenomics 
Prenatal 
Cellular health 
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Doctor 
Patient Direct Intervention 
Order Required 
Yes No 
Yes No 
Yes No 
Yes No 
No Yes 
Yes for Gensona/ No for Gensona/ 
no for PST yes for PST 
No Yes 
Yes Yes 
No Yes 
Yes No 
Yes No 
No Yes 
No Yes 
Yes Yes 
No Yes 
No Yes 
Yes No 
Yes No 
Yes No 
No Yes 
No Yes 
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Table 1. Continued 
Company Name and Web Site Address Tests Offered 
Patient Direct 
Order 
Doctor 
Intervention 
Required 
University of California, San Diego Medical 
Center (http://health.ucsd.edu/specialties/ 
medgenet/) 
Angelman syndrome, Bloom syndrome, Canavan 
disease, and others 
No Yes 
University of Rochester Medical Center 
(http://www.urmc.rochester.edu/genetics/) 
Breast cancer, colon cancer, cystic fibrosis, 
sickle-cell anemia, thalassemia, and other 
hemoglobinopathies 
No Yes 
Vanderbilt's Monroe Carell Jr. Children's 
Hospital (http://vanderbiltchildrens.com/ 
interior.php?mid=l 78) 
Newborn screening, prenatal No Yes 
Vysis Aneuvysion (http://www.aneuvysion.com/) 
Yale Cancer Center (http://www. 
yalecancercenter.org/genetics/index.html) 
appeals used and the numbers of positive and negative 
appeals used. 
Results on Information Practices 
A summary of results from the content analysis and a brief 
description of each variable appear in Table 3. Of 46 DTC 
Web sites, 43.5% allowed consumers to order directly from 
the company. Another 10.9% allowed consumers to order 
test kits directly but required doctor intervention to submit 
samples for analysis or to obtain results. The remaining 
Web sites allowed order placement and/or referral by a 
health care professional only. Test cost information was 
provided on half (52.2%) of the DTC Web sites. Some Web 
sites allowed consumers to order test kits for free but did 
not provide information on the cost of the sample analysis 
and results reporting. We surmised that test kits received by 
consumers would disclose cost information. 
Basic Genetic Information 
The complexity of genetic information makes it critical for 
consumers to receive proper education and assistance in 
understanding such information (Gollust, Hull, and Wilfond 
2002; kSERO Corporation 2003). We examined each Web 
site for explanations of genetic terminology and of how 
genes and genetic tests work. Of the DTC Web sites, 47.8% 
offered such information, often in the form of a glossary or 
a health library. Another 17.4% did not offer basic genetic 
information but provided links to other W eh sites where 
consumers could find such information. Surprisingly, the 
professional Web site group did much worse (x2 = 5.35, p = 
.02), with only 17.6% of the Web sites providing basic 
genetic information and another 17 .6% offering links to 
such information. We observed similar differences between 
professional and consumer sections within a Web site, with 
58.3% providing basic genetic information in the consumer 
section versus only 33.3% in the professional section. 
Another 16.7% of the consumer sections provided links to 
basic genetic information, whereas only 12.5% of the pro-
fessional sections did so. 
Prenatal 
Cancer 
No 
No 
Probabilistic Nature of Genetics 
Yes 
Yes 
As we noted previously, carrying a particular mutation does 
not always entail affliction with the related disease. Con-
sumers who undergo genetic testing should be aware of this 
to avoid unnecessary stress caused by test results that indi-
cate the presence of a mutation. For some consumers, 
knowing the probabilistic nature of genetics may also make 
them decide against taking genetic tests and avoid anxiety. 
Of the DTC Web sites, 45.7% provided information on 
inheritance patterns and the probability of getting a disease 
if a person carries the mutation. For professional-oriented 
Web sites, 47.1 % provided such information. There was no 
significant difference between the consumer (58.3%) and 
the professional (50.0%) sections within a Web site. Three 
(6.5%) DTC Web sites contained statements and language 
reflecting genetic determinism. Notably, all three of these 
Web sites allowed consumers to order directly from them 
without any doctor's intervention, thus leaving consumers 
more susceptible to erroneous decisions that could nega-
tively affect their health. 
Pros and Cons of and Alternatives to Genetic Testing 
Balanced information refers to information on both the 
benefits and the risks of genetic testing. Of the 46 DTC 
Web sites, only 15.2% discussed potential harmful effects 
of genetic testing. The professional Web sites performed 
equally poorly, with only 5.9% offering both pros and 
cons.4 When we compared the consumer and professional 
sections, 16.7% of the consumer sections discussed pros 
"Closely related to the pros and cons of genetic testing is the possibility 
of false positives and/or false negatives (i.e., clinical validity) of the tests 
provided. Our analysis showed that only 26.1 % of the DTC Web sites pro-
vided specific false positive/negative rates, and 10.9% of the Web sites 
mentioned the possibility of a false positive/negative, but they did not give 
any rate. Professional Web sites performed similarly, with 35.3% offering 
false positive/negative rates and another 17 .6% mentioning the possibility 
of a false positive/negative without specific rates. 
Table 2. Professional Genetic Testing Sites 
Company Name and Web Site Address 
Ambry Genetics (http://www.ambrygen.com) 
Athena Diagnostics (http://www.athenadiagnostics.com) 
Baylor Medical Genetics Lab (http://www.bcm.edu/geneticlabs/) 
BRT Laboratories (http://www.rhlab.com/P53.html) 
Case Western University Hospitals 
(http://www.uhhospitals.org/case/OurServices/Centersand 
Programs/GM/ AddictionRecoveryServices/tabid/ 1196/Default. 
aspx) 
Duke Medical Genetics 
(http://medgenetics.pediatrics.duke.edu/modules/services/ 
index.php?id=l) 
Genedx (http://www.genedx.com) 
Kennedy Krieger Institute Genetics Laboratories 
(http://genetics.kennedykrieger.org) 
LSU Health Sciences Center (http://www.lsuhsc.org) 
Molecular Diagnostics Laboratories (http://www.mdl-labs.com/) 
OHSU Cancer Genetics 
(http://www.ohsu.edu/outreach/cdrc/clinical/portland/ 
genetics_cancer.html) 
Prometheus (http://www.prometheuslabs.com/212.asp ?nav=products) 
Robert Guthrie Genetics Lab (http://www.rgbgl.org) 
Stanford Medical Genetics 
(http:/ /pediatrics genetics. stanford.edu/patient_ care) 
UMDNJ Institute of Genomic Medicine 
(http://www. umdnj .edu/genesatwork/) 
University of South Alabama Birth Medical Genetics 
(http://www.southalabama.edu/genetics/bdgc_index.htm) 
University of Washington Genetics Lab 
(http://depts.washington.edu/labweb/Divisions/ 
Mo!Diag/Mo!DiagGen/index.htm) 
and cons, whereas 25.0% of the professional sections 
offered such information. This lack of evenhanded informa-
tion contrasts sharply with the fair balance requirement 
governing DTC advertising of prescription drugs, possibly 
because of the aforementioned confusion over regulatory 
oversight of genetic tests. Although genetic testing may not 
cause the same side effects as prescription drugs, as we dis-
cussed previously, the potential negative financial and psy-
chological effects of genetic testing can be equally severe 
and far-reaching (Cella et al. 2002; Lee and Brennan 2002). 
To exacerbate the lack of balanced information, only 
15.2% of the DTC sites suggested viable alternative means 
of predicting or diminishing the likelihood of being affected 
by a hereditary condition, such as maintaining a healthful 
lifestyle, relying on family history, or taking other non-
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Tests Offered 
Cystic fibrosis, pancreatitis, diabetes, pulmonary diseases, and 
others 
Hearing loss, diabetes, obesity, and others 
Cystic fibrosis, fragile X, osteoporosis, Huntington's disease, 
prenatal, and others 
Cancer tumor suppression 
Cystic fibrosis, fragile X, hearing loss, and others 
Neurofibromatosis, Down syndrome, fragile X, lysosomal 
disorders, and others 
Prenatal, skin disorders, and others 
Peroxisomal disease, prenatal, Canavan disease, and others 
Cancer, prenatal, and others 
Thrombosis 
Cancer 
Celiac disease, metabolism, lactose digestion 
Metabolism, lysosomal storage disease, muscle disease 
Down syndrome, neurology, metabolism, cancer, and prenatal 
Prenatal, sickle-cell anemia, neurofibromatosis, and 
neuromuscular diseases 
Mental retardation, neurofibromatosis, Turner syndrome, Down 
syndrome, fragile X, and others 
Cystic fibrosis, hearing loss, fragile X, Factor V Leiden, 
Huntington's disease, and others 
gene-based tests. This absence is especially pronounced in 
Web sites that allowed direct orders, with 95.0% missing 
information about alternatives. Professional Web sites fared 
no better, with only 11.8% mentioning alternatives to 
genetic testing. We found a similarly low percentage 
(8.3%) in the professional sections of DTC Web sites. 
Without information about alternative approaches and 
potential negative effects of genetic testing, these Web sites 
effectively exaggerate the benefits of genetic testing and 
encourage unnecessary testing. 
Privacy Policy 
The extensive implications of genetics for health care make 
it critical to protect consumers' private information in this 
area (Lerman and Shields 2004). Currently, consumer pri-
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Table 3. Content Analysis Results Summary 
Present in 
Present in DTC Professional Intercoder 
Coding Variable Variable Description Web Sites Web Sites Agreement 
Information 
Basic genetic Information on basic genetic terms and patterns of heritability 47.8% 17.6% 86.7% 
information (e.g., a glossary of terms). 
Probabilistic nature of Information about the probabilistic nature of genetics and 45.7% 47.1% 81.7% 
genetics genetic tests (e.g., probability of getting a disease if a person 
carries the mutation). 
Pros and cons States both pros and cons of the products/services offered. 15.2% 5.9% 96.7% 
Alternatives Alternative means of predicting or diminishing the likelihood of 15.2% 11.8% 93.3% 
being affected by a hereditary condition (e.g., a healthful 
lifestyle and non-gene-based tests). 
Privacy policy Provision of a privacy policy stating the protection of patient 71.7% 52.9% 91.7% 
health information. 
Scientific information Professional information to health care providers (e.g., 54.3% 100% 95.0% 
for health scientific proof of test validity and reliability, disease 
professionals information). 
Emotional Appeals 
Happiness/joy Portrays situations that represent a good feeling, immense 21.7% 0% 91.7% 
pleasure, and even ecstasy; a promise of happiness. 
Warmth Portrays a positive warm and fuzzy feeling that is less intense 60.9% 29.4% 90.0% 
than happiness/joy. 
Pride Portrays a strong sense of self-respect, dignity, and superiority. 4.3% 0% 96.7% 
Empowerment Reflects an enhanced sense of power; appeals to a consumer's 60.9% 11.8% 93.3% 
desire to be in control; it can apply to dealing with both 
desirable and undesirable situations. 
Assurance/peace of Appeals to a sense of peace, knowing for certain of a positive 34.8% 23.5% 90.0% 
mind outcome. 
Relief Portrays a sense of relaxation after removal of something 26.1% 12.5% 90.0% 
stressful; less outcome-related but rather the mere fact that "I 
finally know." 
Fear Portrays a negative, undesirable scenario that may happen in 26.1% 5.9% 96.7% 
order to arouse fear in the audience. 
Guilt/shame Presents actual violation or a potential violation of the 2.2% 5.9% 98.3% 
consumer's internalized standard of proper behavior. 
Regret Portrays a dissatisfactory choice when a better choice 10.9% 0% 93.3% 
is/was possible. 
Sadness Portrays situations representing a downcast mood, unhappiness, 4.3% 0% 98.3% 
and, in the extreme form, grief. 
vacy in the health care industry is protected by the Health 
Insurance Portability and Accountability Act (HIPAA) of 
1996, though HIP AA compliance is likely to be limited and 
varied among online vendors (Choy et al. 2001). Under 
HIP AA, health care professionals cannot share a con-
sumer's health information without the consumer's explicit 
consent. Of the DTC Web sites, 71.7% claimed to follow 
HIP AA guidelines and posted privacy statements pledging 
confidential treatment and protection of consumer informa-
tion. In comparison, 52.9% of the professional Web sites 
had a privacy policy. This lower presence of privacy policy 
may be due to the physician-patient confidentiality rule that 
requires physicians to protect patient information. It is 
worth noting that in May 2008, the Genetic Information 
Nondiscrimination Act was signed into law, with the aim 
to prevent employers and insurance companies from using 
genetic information to the detriment of individuals. 
Although the act is likely to alleviate prospective con-
sumers' fears, how it will affect genetic testing practices 
remains to be seen. 
Scientific Information for Health Care Professionals 
To help consumers make the right decision about genetic 
testing, it is necessary for health care professionals to have 
evidence of the validity and utility of a particular test. Of 
the 46 DTC genetic testing Web sites, only slightly more 
than half (54.3%) offered such information to health care 
professionals. With a low prevalence of professional-
targeted information, these Web sites discourage profes-
sional participation in the decision-making process. 
Although the negative impact can be alleviated by profes-
sional genetic counseling, only 39.1 % of the DTC Web 
sites offered genetic counseling services, and among these, 
only 2 made pretest counseling mandatory. The lack of a 
professional intermediary is dangerous for consumer 
welfare and may also put a strain on the patient-doctor 
relationship. 
Results on the Use of Emotional Appeals 
Our analysis of genetic testing Web sites suggests that far 
from providing only objective information, these Web sites 
appeal often to consumers' emotions. A typical positive 
emotional appeal is the promise or actual experience 
(through user testimonials) of positive outcomes from tak-
ing a test. For example, consumers may experience relief, 
assurance, and happiness when they receive positive test 
results. However, even with the possibility of negative test 
results, many Web sites still promoted the positive feeling 
of empowerment. The reasoning was that knowing about 
heightened risk allows a person to better control or manage 
his or her life and health. Negative emotional appeals were 
also used. Fear was most often portrayed in the pretest stage 
and was often elicited through a family history of a particu-
lar disease or through the severity of threat from a disease. 
In contrast, regret, guilt, and sadness were associated most 
often with potential negative outcomes if a person were not 
to take a test. In some cases, negative emotions were copre-
sented with the promise of positive emotions if a person 
were to take a test, creating a powerful contrast. 
On the use of emotional appeals, our analysis revealed 
significant differences between DTC and professional 
genetic testing Web sites and between consumer and pro-
fessional sections within the same DTC Web sites (for the 
distribution of total emotional appeals used, see Figure 1). 
On average, a DTC Web site used 2.52 emotional appeals, 
whereas professional Web sites used an average of .88 emo-
tional appeals (t = 3.77, p < .001). Compared with profes-
sional Web sites, DTC Web sites used both more positive 
emotional appeals (MoTc = 2.09 versus Mprofessional = .76; 
t = 3.95, p < .001) and more negative emotional appeals 
(MoTC = .43 versus Mprofessional = .12; t = 2.07, p = .04). 
Emotional appeals were also used more in the consumer 
section (M = 2.83) than in the professional section (M = 
1.25; t = 2.79, p = .008). This significant difference is 
attributable mainly to the higher use of positive emotional 
appeals (for consumer sections, M = 2.29, and for profes-
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sional sections, M = 1.00; t = 3.33, p = .002). The number 
of negative appeals did not differ significantly between the 
sections (for consumer sections, M = .54, and for profes-
sional sections, M = .25). 
Use of Emotional Appeals in OTC Web Sites 
The most popular emotional appeals were warmth and 
empowerment, both of which were present in 60.9% of 
DTC Web sites. This frequent use of an empowerment 
appeal is not surprising, because it is the least dependent on 
actual test results and therefore is a versatile, persuasive 
tool. Even more revealing, the prevalence of an empower-
ment appeal varied significantly by whether a Web site 
allowed consumers to order directly (X2 = 13.81, p = .001). 
The appeal was present in 90.0% of the direct-order Web 
sites but in only one-third of the non-direct-order Web sites. 
By using this popular ploy of appealing to a person's desire 
to be in control, the direct-order Web sites may unduly 
encourage consumers to take a genetic test without fully 
understanding the consequences. 
The second most popular positive emotional appeal was 
assurance, which was present in 34.8% of DTC Web sites. 
Relief appeal, which portrays a sense of relaxation after the 
removal of stressful stimuli (e.g., worrying about getting a 
disease), was used by 26.1 % of the DTC Web sites, fol-
lowed by happiness/joy (21.7%). Together, these positive 
emotional appeals attempt to engender a positive feeling 
toward the advertiser, which may have nothing to do with 
what the product actually offers. For example, many Web 
sites portray healthy-looking, smiling people in a warm 
family setting, implying that genetic testing could bring 
about such desirable outcomes. Although the effects of 
these emotion-arousing images may seem subtle to a con-
sumer, prior research suggests that feelings engendered by 
such messages can powerfully influence consumer attitudes 
and purchase intentions (Edell and Burke 1987). 
Although the use of negative emotional appeals was less 
prevalent in all Web sites, a significant portion (26.1 % ) of 
DTC Web sites used fear appeals. As a popular advertising 
tactic, a fear appeal is designed to alert consumers to a 
threatening scenario that leads to a negative consequence. 
By arousing the undesirable emotion of fear, these DTC 
genetic testing Web sites activate consumers' coping 
mechanisms, encourage them to comply with the solutions 
offered, and enhance consumers' attitudes toward the prod-
ucts and services offered (LaTour, Snipes, and Bliss 1996). 
The second most popular negative emotional appeal was 
regret, which was present in 10.9% of DTC Web sites. The 
least common emotional appeals were pride (4.3%), sad-
ness (4.3%), and guilt (2.2%). 
Use of Emotional Appeals Toward Health Care 
Professionals 
Although some of the emotional appeals used often by DTC 
Web sites (e.g., warmth, assurance) were also more domi-
nant in professional sites, three important DTC emotional 
appeals-empowerment (X2 = 12.00, p = .001), warmth 
(X2 = 4.93, p = .03), and happiness/joy (X2 = 4.39, p = 
.04)-were used significantly less by professional Web 
sites. Although empowerment was a major ploy in market-
ing genetic tests to consumers, companies may consider it 
ineffective with professionals, who already wield signifi-
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Figure 1. Distribution of the Number of Emotional Appeals 
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cant power. For professional Web sites, warmth and assur-
ance were the most frequently used emotional appeals, 
which were present in 29.4% and 23.5% of the Web sites, 
respectively. These were followed by empowerment and 
relief (both 11.8% ). Of the professional Web sites, 5.9% 
used fear and guilt, and none employed the other emotional 
appeals (happiness, pride, regret, and sadness). When we 
compared the professional and consumer sections within 
the same Web sites, a few significant differences emerged. 
The professional sections used significantly less happiness/ 
joy (0% versus 29.2%; x2 = 8.20, p = .004), empowerment 
(29.2% versus 54.2%; x2 = 3.09, p = .08), assurance (8.3% 
versus 37.5%; x2 = 5.78, p = .02), and relief (12.5% versus 
33.3%; x2 = 3.04, p = .08) appeals than the consumer sec-
tions. Given that these sections reside within the same Web 
sites, such differences in the use of emotional appeals are 
astounding. It is apparent that companies deliberately 
employ more emotional appeals and present themselves as 
compassionate agents when communicating with con-
sumers, potentially augmenting the persuasive power of 
their marketing messages. 
Policy Recommendations 
Our review of the current state of affairs suggests signifi-
cant problems with existing practices of DTC marketing of 
genetic tests. The current lack of oversight of the genetic 
testing industry leaves consumers vulnerable as they strive 
to protect their welfare without the knowledge or tools nec-
essary to do so. Oftentimes, such a failure to enact specific 
regulations can have a significant impact on social policy 
because its absence allows other forces to shape practices 
and policies; for example, as Clayton (2004) points out, 
litigation against physicians, rather than legislation, led to 
the inclusion of genetic testing in routine prenatal care. 
Although many view routine prenatal testing as a good 
thing, some drawbacks have been observed. For example, 
test results can put some women in the difficult position of 
having to decide whether to continue a pregnancy. Some 
critics of the practice have also noted that the availability of 
prenatal testing has altered society's view of children born 
with genetic diseases-that is, that they should not have 
been born. Furthermore, instead of viewing the birth of an 
impaired child as an unfortunate roll of the genetic dice, 
women are viewed as blameworthy for failing to prevent it. 
The situation with prenatal care reveals the potential 
negative outcomes of policy creation through inaction. 
Although the exact effects of DTC marketing of genetic 
tests remain to be seen, we advocate proactive public policy 
aimed at preventing negative outcomes rather than reactive 
regulations aimed at addressing negative outcomes after 
they have happened. Specifically, on the basis of our 
review, we recommend a three-pronged approach to public 
policy in this area: consumer education, physician interven-
tion and education, and regulation of marketing activities. 
Consumer Education 
I~ discussing consumer vulnerability in the marketplace, 
Rmgold (2005) recognizes the importance of education in 
reducing vulnerability. We concur and recommend a well-
publicized campaign to educate consumers about the risks 
and benefits of genetic testing and to increase awareness of 
existing resources that provide information about genetic 
tests, such as the FTC Web site's concise and helpful 
brochure titled "At-Horne Genetic Tests: A Healthy Dose 
of Skepticism May Be the Best Prescription" (see http:// 
www.ftc.gov/bcp/edu/pubs/consurner/health/hea02.shtrn). 
The American Academy of Family Physicians also has an 
informative Web site on this topic (see http://farnilydoctor. 
org/online/farndocen/horne/healthy/prevention/462.htrnl). 
We propose that a public health campaign use traditional 
mass media to ensure sufficient reach to the public. The 
goals of the campaign would be (1) to increase awareness 
of the complexities of genetic tests and consumers' lack of 
knowledge in this area, (2) to encourage consumers to seek 
more information in their decision making, and (3) to publi-
cize quality information currently available in this area. The 
campaign should also involve industry and professional 
organizations to draw on their expertise and existing 
resources. We believe that the industry should be motivated 
to participate in such a campaign because it may also raise 
awareness of genetic tests. 
This consumer education campaign should work in con-
j~nction with DTC marketing from genetic testing cornpa-
mes. Research on DTC advertising of prescription drugs 
shows that consumers are likely to seek information after 
seeing a DTC advertisement (Calfee 2002; Liu et al. 2005). 
It is reas_onable to expect that exposure to DTC marketing 
of genetic tests may lead to similar behavior. This post-
exposure information seeking is a crucial juncture because 
it can potentially remedy the deficiency in DTC marketing 
and help consumers make the right decision. In an effort 
to direct information seeking to the right sources, public 
education campaigns could be timed to coincide with DTC 
marketing campaigns. Public education materials from 
un~iased s_o~rces could be distributed to patients through 
their phys1c1ans during patient consultation sessions that 
may result from DTC marketing campaigns. Because the 
Internet is a crucial source for health care information 
genetic testing companies should also be encouraged to link 
to these public education materials from their Web sites. 
The ultimate goal of public education is to increase con-
~urners' k?owledge, to empower them, and, effectively, to 
produce mformed decision makers" (Andrews et al. 1994, 
p. 196). 
Physician Intervention and Education 
Public education alone is unlikely to produce sufficient 
knowledge for an average consumer to make sound deci-
~ions about ge?etic_ testing. Physicians will likely play an 
important role m this area. In a study of consumer inforrna-
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tion seeking after exposure to DTC advertising of prescrip-
tion drugs, Liu and colleagues (2005) show that despite 
consumers' stated intentions, they ultimately sought physi-
cian consultation about drugs they had seen advertised. 
Although consumers intended to use the Internet as a sub-
stitute, it ended up being a supplement rather than a 
replacement. Because physicians are also likely to be key 
players in genetic testing, it is important to clarify their role 
in this process and to educate and prepare them for the 
genomic era. 
Physician Intervention 
In formulating public policy in this area, useful guidance 
can be drawn from the distinction between prescription and 
over-the-counter drugs. Currently, the FDA can approve a 
change in a drug's status from prescription-only to over-
the-counter if its benefits have been proved to outweigh its 
risks, if consumers can self-diagnose their conditions and 
easily understand the drug's label, and if the potential for 
abuse is low (Cohen, Paquette, and Cairns 2005; Jacobs 
1998). These rules imply that it may be too soon to allow 
"over-the-counter genetic tests." Although the effects of 
genetic tests vary from the side effects of prescription 
drugs? uncertainty about the consequences of undergoing 
genetic tests makes it inappropriate to assume that the bene-
fits w_ill outweigh the risks. Furthermore, although genetic 
test kit labels can be made relatively accessible, a key step 
in "consuming" genetic tests is the interpretation of test 
results, which is much trickier for the average consumer. 
The probabilistic nature of genetics and many other factors 
that affect a consumer's health condition make accurate 
self-diagnosis and determination of an appropriate course of 
treatment difficult. Thus, genetic self-tests at this time 
would fail to meet classification criteria similar to those 
used to designate drugs as over-the-counter. 
~or these reasons, we recommend that predictive genetic 
testmg be offered only through a physician intermediary 
and t~at patients be discouraged from undergoing genetic 
tests m the absence of indications that it would be useful 
(~-_g., !amily history, clinical symptoms). When clinical jus-
tification for a genetic test is lacking but the patient's desire 
for it is present, the physician should warn the patient of 
"the possibility of psychological stress induced by knowl-
edge _that the test will reveal" (Bayley 2004, p. 183). This 
warnmg_s~~uld accompan~ ~he usual information regarding 
t~e poss1b1hty of false-pos1t1ve, false-negative, or inconclu-
SIVe results, as well as about the likely clinical and personal 
value of the test for the patient. Moreover, patients should 
be warned that even if a positive result is later discon-
firmed, the initial positive result might cause short- or long-
term psychological distress. In agreement with Munson 
(2007), however, we acknowledge that a test's lack of clin-
ical value does not mean that its results are of no value to 
the pati~nt; there may be defensible reasons for undergoing 
a genetic test even if it does not facilitate prevention or 
treatment of a disease. For this reason, we recommend a 
prohibition on DTC marketing of genetic tests that lack 
analytic or clinical validity, but we withhold such a recom-
mendation for tests that merely lack clinical utility. 
Although our recommendation is more restrictive than 
the recent American Society of Human Genetics statement 
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(Hudson et al. 2007), our decision is based on the current 
lack of other protections that are in place. In the future, as 
more data on the effects of genetic tests on consumer health 
and welfare become available, we may alter this conclusion. 
Eventually, over-the-counter-like status for some genetic 
tests may be reasonable, but a clear guideline for conver-
sion must first be established. The guideline must consider 
the test's analytical and clinical validity, the prevalence and 
nature of the target disease, and whether test results will 
prompt consumers to alter their behavior and how. Along 
these lines, Javitt (2007, p. 646) proposes "a tiered 
approach that matches the level of risk to the degree of 
[FDA] oversight"; that is, the regulatory focus should not 
be on whether the test is a laboratory-developed test or is 
sold as a kit (Javitt 2007; Katsanis, Javitt, and Hudson 
2008). 
Initially, it might be expected that genetic testing compa-
nies would resist the physician intervention requirement, 
but self-interest may dictate their support for such a move. 
In Pines' s ( 1999) discussion of DTC marketing of prescrip-
tion drugs, he notes that pharmaceutical companies have 
often employed the "learned intermediary" defense, claim-
ing that they are clear of liability because the use of the 
drug is controlled not by the pharmaceutical companies but 
by the health care professionals whose duty is to inform the 
patient regarding risks, benefits, and proper use of the drug. 
Using Perez v. Wyeth as an example,5 Pines (1999, p. 515) 
notes that DTC advertising "alters the calculus of the 
learned intermediary [such that] the learned intermediary 
doctrine 'does not apply to direct marketing of drugs to 
consumers."' Consequently, in the interest of protecting 
themselves from potential legal liability, genetic testing 
companies may welcome physicians as gatekeepers and 
refrain from DTC selling. 
Physician Education 
Although there are good reasons physicians may favor their 
role as gatekeepers (e.g., better management of relationship 
with patients, protection of consumer welfare, increased 
revenue), existing evidence shows that physicians-pri-
mary care physicians, in particular-are still somewhat 
reluctant to integrate genetic testing into their practices 
(Bayley 2004). This may be partially due to their current 
lack of knowledge of genetics and an accompanying lack of 
confidence in handling requests for genetic tests or inter-
preting test results. Although medical schools are improv-
ing genetics education, many physicians currently practic-
ing medicine received inadequate training in clinical 
genetics; thus, many on the front line are unprepared to deal 
with patients' inquiries about genetic testing (Bayley 2004). 
To address this issue, significant improvements in genetics 
education in medical schools, residency programs, and con-
tinuing medical education programs are necessary. The 
National Coalition for Health Professional Education in 
Genetics is currently working to improve physician knowl-
edge of genetics. This group has recently created a CD 
titled Genetics and Common Disorders: Implications for 
Primary Care and Public Health Providers, which can be 
5Saray Perez v. Wyeth Labs., Inc., 734 A. 2d 1245 (N.J. 1999). 
obtained for free through the Internet and used for educa-
tional purposes. With the rapid advances in genetic medi-
cine and a new interest in its possible role in preventive 
care, physicians will likely welcome educational programs 
that help them function more effectively. 
Regulation of OTC Marketing of Genetic Tests 
Regulation of DTC marketing of genetic tests must address 
quality control and content of marketing communication. In 
terms of quality control, in accordance with the recommen-
dations of the National Institutes of Health Task Force on 
Genetic Testing ( 1997) and Munson (2007), we propose a 
prohibition on offering to the public any genetic test that is 
not analytically valid. Furthermore, we recommend that 
either the FDA or the CMS publish a clear and accessible 
list of analytically and clinically valid tests and widely pub-
licize its existence so that both providers and laypersons 
can easily determine whether the test they intend to use has 
been shown to be accurate. We agree with Javitt's (2007, p. 
647) recommendation that the FDA and CMS jointly 
develop a "guidance document outlining the type of data 
required to support [a claim of] clinical validity." Further-
more, a link to this resource should be included in the stan-
dard information section that we propose should be 
included in every DTC genetic testing Web site. Exposing 
consumers to this list would help correct the mistaken belief 
that all genetic tests on the market are FDA approved or 
scientifically valid (Donohue, Cevasco, and Rosenthal 
2007; Javitt 2007). We also recommend that the CMS pro-
vide a clear and accessible resource for determining 
whether labs conducting genetic tests are qualified to do so. 
Regarding the content of DTC marketing communica-
tion, we recommend that more specific guidelines be 
devised for genetic tests and that, in agreement with Javitt 
(2007) and Katsansis, Javitt, and Hudson (2008), FDA and 
FTC enforcement of existing prohibitions against mislead-
ing advertisements be intensified. Beyond the truthful 
advertising and fairness principles governing all advertise-
ments, regulation of marketing communications in this area 
needs to consider the intricate nature of genetic tests and 
their far-reaching effects on consumer health and social 
welfare. Although the FDA regulation of DTC advertising 
of prescription drugs may be a useful guide in formulating 
policy in this area, its limitations, such as the lack of clarity 
and its inadequate consideration of laypersons (Pines 1999), 
must also be acknowledged and addressed. Minimally, we 
recommend that all DTC marketing materials specify the 
potential harms of a test, point out the probabilistic nature 
of genetics, and provide indicators of test accuracy and 
utility. 
Internet-Specific Issues 
According to a PEW Internet & American Life study, only 
15% of online health information seekers examined the 
source and date of online resources (Fox 2006), leaving 
most consumers vulnerable to incorrect and low-quality 
information. These findings, together with our analysis, 
suggest a need to regulate online marketing materials. 
Although the FTC (2000) has specified that its laws are not 
media specific and thus apply to the Internet, regulations of 
online genetic test marketing need to address at least two 
unique issues: presentation of information and linking to 
external information. 
Presentation of Information 
A unique aspect of online resources is the often-complex 
navigational structure of Internet sites, which makes them 
trickier to regulate than traditional advertisements. This 
raises two issues. First, the amount of space available on the 
Internet enables a Web site to offer far more information 
than traditional marketing media. However, increased quan-
tity provides no assurance of good quality. As a Journal of 
the American Medical Association editorial notes, "The 
problem is not too little information but too much, vast 
chunks of it incomplete, misleading, or inaccurate" (Sil-
berg, Lundberg, and Musacchio 1997, p. 1244). Genetic 
science is complex even in small doses, and in any case of 
information overload, comprehension of the material can be 
lost. Second, Web site content is not always presented in a 
way that promotes sound decision making. As the FTC 
(2000) points out, companies sometimes present critical 
information, such as disclosures, in such a way that it is eas-
ily overlooked by consumers. During our analysis, we often 
needed to drill down deep into a Web site to find certain 
information. Given the more casual nature of most con-
sumers' information searches, there is reason to doubt that 
consumers will find the information needed to make 
informed decisions. 
To address these issues, we recommend that a standard 
section be included in every DTC genetic testing Web site. 
The information in this section should be written in lay-
man's terms so that an average consumer can easily under-
stand it. A link to this standard section should be promi-
nently displayed on every page within the Web site for easy 
access. Standardized icons can also be created to identify 
information in the section so that consumers can easily 
compare multiple DTC Web sites. The goal of this standard 
section is to offer objective, accessible information to help 
consumers make prudent decisions about whether to 
undergo a certain test. 
We expect that the presence/absence of this standard sec-
tion could function as a starting point for creating an online 
list of FTC-compliant and noncompliant companies. 
Although enforcing regulations in an online environment is 
likely to be significantly more challenging than in the 
bricks-and-mortar context, the 24-7 public availability of 
online materials makes it considerably easier to monitor 
Web sites for compliance. The new mentality of consumer 
participation and collaboration in the newer generation Web 
may propel grassroots-level monitoring (Tapscott and 
Williams 2006). If the FTC lacks the resources to conduct 
all the monitoring itself, other interested groups or individu-
als may do so on a volunteer basis after the FTC clearly 
establishes the compliance criteria. 
Linking to External Information 
New regulations should also specify firms' obligations and 
liability for external information linked from their Web 
sites. Many of the genetic testing sites we analyzed con-
tained convenient links to information from third-party 
sources, some of which functioned as endorsements for the 
products or services marketed by the referring site. Such 
information can have a persuasive effect in favor of the 
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referring site; yet in the current regulatory climate, it is 
unclear under what conditions firms are held responsible 
for hyperlinked information. As a result, it has been sug-
gested that companies can reduce liability by linking to the 
external source's home page rather than to a specific page 
within that external site and by displaying explicit dis-
claimers before consumers navigate to the external Web site 
(Heather 2001). Although these measures may diminish lia-
bility, they do not necessarily reduce the persuasive effect 
of such information on consumers. We recommend creating 
specific guidelines that will close such loopholes and thus 
protect consumers. 
In his work on online marketing of prescription drugs, 
Heather (2001) suggests that the treatment of hyperlinked 
external information from pharmaceutical companies' Web 
sites can be partially borrowed from guidelines used in the 
investment community. Specifically, the Securities and 
Exchange Commission (2000) considers three factors when 
determining liability for hyperlinked information: ( 1) con-
text of the link, such as whether the referring site explicitly 
endorses the external information; (2) risk of confusion by 
users about information sources; and (3) presentation of the 
linked information, such as the actual external page that is 
linked to and the layout of the link in the referring site. 
Similar guidelines can be issued on how hyperlinked infor-
mation from genetic testing companies' Web sites should 
be treated. 
Resource Considerations 
In recommending more stringent regulations, we acknowl-
edge the necessary costs that come with implementing such 
regulations. Currently, FDA staff and other resources are 
limited. However, in the interest of protecting public health, 
conserving individual and collective health care resources, 
and preserving the present and future credibility of genomic 
science, Congress should give greater priority to providing 
adequate funding for oversight and regulation of genetic 
tests. This is especially critical given the likely expansion of 
the role of genetics in twenty-first-century health care. 
In the meantime, creative solutions can be used to draw 
available resources from various entities and, thus, to lessen 
the burden on one particular agency. Here, we offer a few 
possibilities. First, as we mentioned previously, the CMS 
has moved toward establishing a specialty area for genetic 
testing. Given the rapid development of the field, reconsid-
ering such a specialty area may constitute a quick and effi-
cient solution because some preparation may have been 
done previously in anticipation of establishing the area. 
Second, in addition to government agencies, it may be 
desirable to appeal to the prudential interests of companies 
that market their tests directly to consumers. However, this 
strategy is unlikely to be effective in all cases. Therefore, it 
may be necessary to align the interests of these companies 
with public welfare in other ways. For example, it is in 
insurance companies' long-term interest to pay only for 
tests that are analytically and clinically valid because only 
such tests are likely to lead to long-term health benefits. 
This may discourage genetic testing service providers from 
marketing bogus genetic tests because such tests will incur 
out-of-pocket expenses and thus put the marketer at a 
competitive disadvantage. Finally, as we discussed in the 
preceding section, the open nature of the Internet facilitates 
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collaborative citizen efforts in implementing regulation 
through this medium. This involvement of civil and trade 
organizations can further lessen the burden on limited fed-
eral resources. 
Further Research 
In this study, we assessed the status of DTC marketing of 
genetic tests and regulations in this area. Our analysis 
revealed that current business practices are problematic and 
that existing public policy has largely neglected to address 
these problems. Combined with consumers' lack of knowl-
edge, this is an undesirable situation. Consequently, we 
issue a call to marketing and ethics scholars to contribute to 
a sound genetic testing marketplace through continued 
inquiry into the impact of genetic tests and the DTC mar-
keting of such tests on individual consumers and society as 
a whole. A few topics deserve special attention. 
First, although this research assesses current business 
practices, our understanding is incomplete without knowl-
edge of how consumers respond to these marketing mes-
sages. Can consumers process these messages and discern 
misleading information? How and to what extent does 
information from DTC marketing sources affect con-
sumers' decision making? More generally, how do genetic 
test results alter consumers' health-related decision mak-
ing? Consumer information-processing and decision-
making theories, especially as they relate to consumer 
knowledge (e.g., Alba and Hutchinson 2000), will prove 
useful in answering these questions. Furthermore, recent 
research shows that both the content and the design of a 
DTC Web site can affect consumer information processing 
and attitudes (Sewak et al. 2005). In this research, with the 
exception of emotional appeals, we focused primarily on 
the informational aspect of DTC Web sites. This can be 
extended in the future to include executional elements of a 
Web site. Further research should also include a more in-
depth examination of the quality of information provided 
on genetic testing Web sites. 
Second, further research should focus on health care pro-
fessionals. With the extensive impact of genetic sciences on 
the health care industry, the ready availability of genetic 
tests to consumers is bound to affect the nature of patient 
care. Related to our policy recommendations, it is necessary 
to better understand physicians' knowledge of and attitude 
toward genetic tests. Researchers should also examine the 
marketing of genetic tests targeted specifically toward 
health care professionals to determine its impact on their 
knowledge, judgment, and practices. Moreover, similar to 
studies of DTC advertising of prescription drugs, 
researchers should examine the impact of DTC marketing 
of genetic tests on patient-physician relationship. It would 
be particularly worthwhile to examine the potential inter-
action between DTC marketing and professional-targeted 
marketing on patient-physician relationship and on market 
outcomes. Research in these areas would enable a more 
accurate assessment of the impact of DTC marketing of 
genetic tests on public health and consumer welfare. 
Third, further research could also address the impact of 
expanded genetic testing on the practice of informed con-
sent. The many unknowns in clinical genetics call into 
question the very possibility of informed consent as tradi-
tionally construed. Will the expansion of genetic testing 
require the retooling of informed consent requirements? 
Does the emphasis on individual autonomy, so prominent in 
U.S. bioethics and medical practice, make sense when faced 
with complex genetic information? Although we recom-
mend improved education of the public and increased 
awareness of the need for scrutiny of claims about genetic 
tests, it is doubtful that the extent of transformation of the 
public will render guidance from genetic professionals 
unnecessary. The current emphasis on individual autonomy 
and "value-neutral" genetic counseling, which some have 
already begun to question, will become more problematic to 
sustain in the face of complex genetic information and the 
decisions that will be based on it. 
Finally, an inquiry into the impact of DTC access to 
genetic tests on particular groups would be an important 
area for further research. Along these lines, De Melo-
Martin (2006a) cautions against ignoring the social contexts 
in which people must decide whether to undergo genetic 
testing, at the risk of reinforcing and perpetuating injustices 
against vulnerable or underprivileged groups. This includes 
consideration of, for example, access to resources that will 
be needed by those who undergo genetic testing. Policy 
makers should work to narrow gaps between DTC access to 
genetic tests and the means to treat or prevent the problems 
revealed or predicted by these tests. It is already the case 
that women's experience with genetic tests and any accom-
panying burdens is, for various reasons, greater than that 
of most men (De Melo-Martin 2006a). Thus, it would be 
important to examine the distribution of benefits and bur-
dens of genetic testing across gender and socioeconomic 
lines and formulate means of amending any inequitable 
distribution. 
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